(Q38224994)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24981455%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

Differentiated thyroid cancer-personalized therapies to prevent overtreatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24981455%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24981455%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Markus Luster

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24981455%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Frederik A Verburg

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24981455%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

publication date

1 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24981455%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Endocrinology

21 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24981455%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24981455%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24981455%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

563-574

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24981455%20AND%20SRC:MED&resulttype=core&format=json

The incidence of thyroid cancer is affected by the characteristics of a healthcare system

21 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Variation in the management of thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Preoperative diagnosis of benign thyroid nodules with indeterminate cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Combined (99m)Tc-methoxyisobutylisonitrile scintigraphy and fine-needle aspiration cytology offers an accurate and potentially cost-effective investigative strategy for the assessment of solitary or dominant thyroid nodules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Peace of mind for patients with differentiated thyroid cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Surgery for papillary thyroid carcinoma: is lobectomy enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Nodal recurrence in the lateral neck after total thyroidectomy with prophylactic central neck dissection for papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Patterns of structural recurrence in papillary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Systematic evaluation of prophylactic neck dissection for the treatment of papillary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Routine prophylactic central neck dissection for low-risk papillary thyroid cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Intraoperative monitoring of the recurrent laryngeal nerve in thyroid surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Predicting the need for calcium and calcitriol supplementation after total thyroidectomy: results of a prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Thyroid Na+/I- symporter. Mechanism, stoichiometry, and specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Papillary and follicular thyroid cancer: impact of treatment in 1578 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Strategies of radioiodine ablation in patients with low-risk thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Dosimetry and thyroid cancer: the individual dosage of radioiodine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Radioiodine for remnant ablation and therapy of metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Associat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

I-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with I-131 in post-thyroidectomy thyroid cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Cytotoxic chemotherapy for differentiated thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Molecular genetics and diagnosis of thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

A piece of the puzzle: what does BRAF status mean in the management of patients with papillary thyroid carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Transient hypoparathyroidism following thyroidectomy: a prospective study and multivariate analysis of 604 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Guidelines for radioiodine therapy of differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Central lymph node dissection in patients with papillary thyroid cancer: a population level analysis of 14,257 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Risk factors of hypoparathyroidism following total thyroidectomy for thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Results of the Thyroid Cancer Alliance international patient/survivor survey: Psychosocial/informational support needs, treatment side effects and international differences in care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Extent of surgery affects survival for papillary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Continuous vagal IONM prevents recurrent laryngeal nerve paralysis by revealing initial EMG changes of impending neuropraxic injury: a prospective, multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Nerve stimulation in thyroid surgery: is it really useful?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

[Permanent hypoparathyroidism due to thyroid cancer surgical procedures in patients exposed to radiation in the Chernobyl, Ukraine, nuclear reactor accident]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Post-thyroidectomy hypocalcemia. Incidence and risk factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Frequent adverse events after treatment for childhood-onset differentiated thyroid carcinoma: a single institute experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Long-term results and prognostic factors in patients with differentiated thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Papillary and follicular thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Follow-up of patients with thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

A comparison of prognostic classification systems for differentiated thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

124I-PET/CT images of differentiated thyroid cancer patients. Distinguishing lymph node metastases from thyroid remnants using kinetic quantities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Observing micopapillary thyroid cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.100

Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal

31 March 2020

1 reference

12 December 2020

A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example

1 reference

12 December 2020

Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma

1 reference

12 December 2020

The use of dosimetry in the treatment of differentiated thyroid cancer.

1 reference

12 December 2020

Morbidity and mortality in follicular thyroid cancer

1 reference

12 December 2020

Risk factors for postthyroidectomy hypocalcemia

1 reference

12 December 2020

Pioglitazone therapy in progressive differentiated thyroid carcinoma

1 reference

12 December 2020

Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?

1 reference

12 December 2020

Differentiated thyroid cancer in childhood: pathology, diagnosis, therapy

1 reference

12 December 2020

A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer

1 reference

12 December 2020

Multicenter study differentiated thyroid carcinoma (MSDS). Diminished acceptance of adjuvant external beam radiotherapy.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2014.100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24981455%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference